231 results about "Myasthenia gravis" patented technology

The present invention relates to a ring amino acid adsorbing agent and its preparation method. It uses natural macromolecule as carrier, its grain size is 0.45-0.9 mm, it is formed from resin which has amino acid ligand with fixed effective dose after activation of epoxy chloropropane, in which amino acid content is 12.5-39.7 micro mol/ml resin, and the described ligand is: amino acid, polyamino acid, polypeptide or protein. It can be directly used for blood perfusion method to cure the diseases of rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, endotoxemia and infective shock, etc. The animal tests show that adsorbing agent has no toxic side effect and heat source. It is a good medical blood-cleaning adsorption material.

The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.

Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.

Compositions and methods of using same are provided for the treatment of neurodegenerative disorders such as Glaucoma, Multiple Sclerosis, Myasthenia Gravis, Diabetic Neuropathy, Cerebrovascular accident, spinal cord injuries, ALS, Parkinson's disease and Idiopathic dementia.

Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor alpha -subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthenogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

The present invention is directed to methods for controlled and optimized removal of cerebrospinal fluid (CSF) from the CSF space of a patient. The methods are particularly intended for the treatment of Alzheimer's disease and other conditions which are caused by, or otherwise related to, the retention and/or accumulation of toxic substances in the CSF. One aspect of the present invention provides a method for shunting toxic substances present in a brain ventricle to the sinus system of an individual suffering from, or at risk of developing, a condition related to the retention and/or accumulation of toxic substances in the CSF, such as Alzheimer's disease. In addition to Alzheimer's disease, the present invention will be useful for treating other conditions resulting from the accumulation of toxic substances and resulting lesions in the patient's brain, such as Down's Syndrome, hereditary cerebral hemorrhage with amyloidosis of the Dutch-Type (HCHWA-D), epilepsy, narcolepsy, Parkinson's disease, polyneuropathies, multiple sclerosis, amyotrophic lateral sclerosis (ALS), myasthenia gravis, muscular dystrophy, dystrophy myotonic, other myotonic syndromes, polymyositis, dermatomyositis, brain tumors, Guillain-Barre-Syndrome, and the like.

The invention relates to a traditional Chinese medicine composition for treating myasthenia gravis. The traditional Chinese medicine composition concretely comprises the following raw medicinal materials in parts by weight: 120-180 parts of astragalus membranaceus, 20-50 parts of radix pseudostellariae, 30-60 parts of codonopsis pilosula, 20-30 parts of bighead atractylodes rhizome, 6-10 parts of bupleurum chinense, 6-10 parts of rhizoma cimicifugae, 6-10 parts of angelica sinensis, 20-50 parts of Chinese yam, 6-10 parts of cortex albiziae, 15-40 parts of prepared fleece flower root, 6-20 parts of morinda officinalis, 6-20 parts of mulberry, 3-6 parts of liquorice, 3-6 parts of pericarpium citri reticulatae, 3-6 parts of fructus aurantii, 20-30 parts of caulis spatholobi, 10-20 parts of medlar and 5-12 parts of radix ophiopogonis. The traditional Chinese medicine composition can be used for strengthening the middle warmer and benefiting vital energy, strengthening the spleen and tonifying the kidneys, and soothing the liver and regulating qi as to a patient with myasthenia gravis, and clinical cure is achieved.

The invention provides an adsorbent, a preparation method thereof, and an adsorption device for blood perfusion. The adsorbent is prepared by bonding phosphate group in DNA molecules to diazo acetic acid esterified polystyrene-divinyl benzene microspheres through covalent bonds. The preparation method comprises the following steps: preparing polystyrene-divinyl benzene microspheres, carrying out chloromethylation, carrying out alcoholization, and performing diazo acetic acid esterification to obtain the adsorbent. The adsorption device comprises the provided adsorbent. The adsorbent has a specific absorbing performance on anti-ds-DNA antibody. Through the covalent bond, the DNA can be more firmly loaded on the solid carriers, the efficiency is higher, and the DNA will not fall off from the carrier during the process of sterilization, storage, and using. The adsorbent can be applied to SLE and can also applied to autoimmune diseases such as myasthenia gravis, Guillain-Barre syndrome, rheumatoid arthritis, hypersensitive organ transplant patients, and the like.

The invention provides a method for determining residual organic solvents in the freeze-dried injection of a traditional Chinese medicine composition. The raw materials of the freeze-dried injection of the Chinese medicine include ginseng and epimedium, which are clinically used for motor neuron diseases (amyotrophic lateral sclerosis, amyotrophic lateral sclerosis, spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis), progressive muscular dystrophy, congenital myopathy and other diseases caused by muscular atrophy and myasthenia gravis, the method of the present invention uses the top The residual amount of organic solvent can be determined by air chromatography, which can be used for the quality control of the product.

The invention relates to a Chinese medicament for treating amyotrophy, myositis, myasthenia gravis and muscular dystrophy. The medicament comprises the following raw material medicinal herbs (by weight portion): Ganoderma capense (Lloyd) Teng 5-120, Phellinus igniarius 5-115, Ganoderma apparatus 5-125, the preferred weight ratio of the constituents includes Ganoderma capense (Lloyd) Teng 20, Phellinus igniarius 15, Ganoderma apparatus 25.

The invention discloses a lentiviral plasmid expression vector as well as a construction method and an application of the lentiviral plasmid expression vector. The lentiviral plasmid expression vector is pCDH-MCS-MuSK-GFP and the nucleotide sequence of the lentiviral plasmid expression vector is shown in SEQ ID NO. 2 in a sequence table. The invention further discloses an application of the lentiviral plasmid expression vector in construction of an anti-muscle-specific receptor tyrosine kinase antibody detection. According to the invention, a stable transfected cell line of MuSK is established by constructing a viral vector, a MuSK antibody is qualitatively and quantitatively detected clinically by an immunofluorescence staining method with relatively high sensitivity and specificity in combination with a flow cytometry, the detection results are more stable and manpower and time costs are greatly saved. The diagnosis and treatment levels of myasthenia gravis are greatly improved by the establishment of the project, the labor capacity and life quality of patients are improved and the lentiviral plasmid expression vector has significant social and economic benefits.

The invention discloses traditional Chinese medicine composition for treating child myasthenia gravis. The traditional Chinese medicine composition is prepared from Chinese herbal raw materials in parts by weight as follows: 10-120 parts of membranous milkvetch roots, 10-30 parts of pilose asiabell roots, 10-20 parts of largehead atractylodes rhizomes, 5-8 parts of Chinese thorowax roots, 5-8 parts of largetrifoliolious bugbane rhizomes, 5-10 parts of Chinese angelica, 5-10 parts of common macrocarpium fruits, 5-10 parts of medicinal indianmulberry roots, 5-10 parts of south dodder seeds, 8-24 parts of Chinese yams, 6-30 parts of prepared tuber fleeceflower roots, 5-12 parts of suberect spatholobus stems, 5-12 parts of fructus lycii, 3-6 parts of liquorice, 3-6 parts of tangerine peel and 3-10 parts of dwarf lilyturf tubers. The traditional Chinese medicine composition is reasonably prepared, does not have toxic or side effects, is convenient to process, low in cost and suitable for popularization and use in clinic and has a remarkable treatment effect on child myasthenia gravis.

A Chinese medicine preparation for treating myasthenia gravis belongs to the technical field of Chinese medicine preparations and is mainly composed of sixteen raw material medicines including astragalus mongholicus, salvia miltiorrhiza, gastrodia elata, scorpio, red flower, herba epimedii, kudzuvine root, nux vomica, lycopodium clavatum and the like. The Chinese medicine preparation for treating the myasthenia gravis has the effects of invigorating spleens and kidneys, promoting blood circulation, removing blood stasis and dredging medians, has the remarkable curative effect on the myasthenia gravis, has no toxic and side effects, and can fasten recovery of a patient.

The invention relates to stemona root alkaloid monomer components and applications thereof. The stemona root alkaloid monomer components are stenin, neostenine, sessilifoline B, and neotuberostemonin, and are used for preparing acetylcholinesterase inhibitors. The invention relates to the applications of the stemona root alkaloid monomer components in preparing medicines used for preventing and treating Alzheimer's disease, bowel obstruction, myasthenia gravis, or glaucoma. The stemona root alkaloid monomer components can also be used for preparing medicines used for improving intelligence.